Wells Fargo
DTIL icon

Wells Fargo’s Precision BioSciences DTIL Stock Holding History

Wells Fargo’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Buy
20,128
+19,961
+11,953% +$140K ﹤0.01% 5333
2026
Q1 		$919 Buy
167
+132
+377% +$609 ﹤0.01% 6345
2025
Q4 		$146 Hold
35
– – ﹤0.01% 6405
2025
Q3 		$193 Sell
35
-33
-49% -$158 ﹤0.01% 6349
2025
Q2 		$286 Buy
68
+33
+94% +$163 ﹤0.01% 6421
2025
Q1 		$167 Hold
35
– – ﹤0.01% 6340
2024
Q4 		$133 Sell
35
-300
-90% -$2.19K ﹤0.01% 6394
2024
Q3 		$3K Hold
335
– – ﹤0.01% 6009
2024
Q2 		$3.26K Sell
335
-526
-61% -$6.2K ﹤0.01% 5941
2024
Q1 		$11.7K Buy
861
+603
+234% +$7.38K ﹤0.01% 5717
2023
Q4 		$2.82K Buy
258
+2
+0.8% +$22 ﹤0.01% 6041
2023
Q3 		$2.62K Hold
256
– – ﹤0.01% 6052
2023
Q2 		$4.03K Sell
256
-8
-3% -$183 ﹤0.01% 6107
2023
Q1 		$5.97K Buy
264
+10
+4% +$330 ﹤0.01% 6005
2022
Q4 		$9.06K Sell
254
-85
-25% -$3.36K ﹤0.01% 5587
2022
Q3 		$13K Sell
339
-26
-7% -$1.24K ﹤0.01% 5572
2022
Q2 		$18K Sell
365
-1,925
-84% -$113K ﹤0.01% 5501
2022
Q1 		$211K Sell
2,290
-532
-19% -$72.3K ﹤0.01% 4949
2021
Q4 		$626K Sell
2,822
-1,570
-36% -$439K ﹤0.01% 4483
2021
Q3 		$1.52M Buy
4,392
+2,157
+97% +$731K ﹤0.01% 3901
2021
Q2 		$840K Buy
2,235
+36
+2% +$10.8K ﹤0.01% 4323
2021
Q1 		$682K Sell
2,199
-536
-20% -$188K ﹤0.01% 4506
2020
Q4 		$685K Buy
2,735
+202
+8% +$49.5K ﹤0.01% 4295
2020
Q3 		$468K Sell
2,533
-537
-17% -$107K ﹤0.01% 4391
2020
Q2 		$768K Sell
3,070
-839
-21% -$184K ﹤0.01% 4021
2020
Q1 		$706K Buy
3,909
+2,698
+223% +$706K ﹤0.01% 3782
2019
Q4 		$505K Sell
1,211
-19,904
-94% -$6.25M ﹤0.01% 4358
2019
Q3 		$5.31M Sell
21,115
-8,320
-28% -$2.71M ﹤0.01% 2485
2019
Q2 		$11.7M Buy
29,435
+11,774
+67% +$4.74M ﹤0.01% 1847
2019
Q1 		$9.51M Buy
+17,661
New +$9.38M ﹤0.01% 1982

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Wells Fargo's DTIL Position: Q2 2026 in Review

Wells Fargo increased its Precision BioSciences (DTIL) stake by 11,953% in Q2 2026, buying an estimated $140K and bringing the position to 20,128 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #5333.

Wells Fargo first reported a position in DTIL in Q1 2019 and has held it in 30 quarters since. The position peaked at $11.7M in Q2 2019. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Wells Fargo held 20,128 shares of Precision BioSciences worth $158K as of Q2 2026.
  • Wells Fargo bought 19,961 Precision BioSciences shares in Q2 2026, an estimated $140K.
  • Precision BioSciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5333 holding.
  • Wells Fargo first reported a position in Precision BioSciences in Q1 2019 and has held it in 30 quarters since.
  • Wells Fargo's Precision BioSciences position peaked at $11.7M in Q2 2019.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.